1. Metabolic Enzyme/Protease
    Anti-infection
  2. HIV Protease
    HIV

Ritonavir (Synonyms: A 84538; ABT 538; Abbott 84538; NSC 693184; RTV)

Cat. No.: HY-90001 Purity: 99.55%
Data Sheet SDS Handling Instructions

Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.

For research use only. We do not sell to patients.
Ritonavir Chemical Structure

Ritonavir Chemical Structure

CAS No. : 155213-67-5

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
10 mg $50 In-stock
50 mg $110 In-stock
100 mg $150 In-stock
500 mg $350 In-stock
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.

In Vitro

Ritonavir is an inhibitor of CYP3A4 mediated testosterone 6β-hydroxylation with mean Ki of 19 nM and also inhibits tolbutamide hydroxylation with IC50 of 4.2 μM[1]. Ritonavir is found to be a potent inhibitor of CYP3A-mediated biotransformations (nifedipine oxidation with IC50 of 0.07 mM, 17alpha-ethynylestradiol 2-hydroxylation with IC50 of 2 mM; terfenadine hydroxylation with IC50 of 0.14 mM). Ritonavir is also an inhibitor of the reactions mediated by CYP2D6 (IC50=2.5 mM) and CYP2C9/10 (IC50=8.0 mM)[2]. Ritonavir results in an increase in cell viability in uninfected human PBMC cultures. Ritonavir markedly decreases the susceptibility of PBMCs to apoptosis correlated with lower levels of caspase-1 expression, decreases in annexin V staining, and reduces caspase-3 activity in uninfected human PBMC cultures. Ritonavir inhibits induction of tumor necrosis factor (TNF) production by PBMCs and monocytes in a time- and dose-dependent manner at nontoxic concentrations[3]. Ritonavir inhibits p-glycoprotein-mediated extrusion of saquinavir with an IC50 of 0.2 μM, indicating a high affinity of ritonavir for p-glycoprotein[4]. Ritonavir inhibits human liver microsomal metabolism of ABT-378 potently with Ki of 13 nM. Ritonavir combined with ABT-378 (at 3:1 and 29:1 ratios) inhibits CYP3A (IC50=1.1 and 4.6 μM), albeit less potently than Ritonavir (IC50=0.14 μM)[5]

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01074931 Abbott HIV-1 Infections April 2008
NCT02503462 University Hospital, Basel, Switzerland AIDS-related Dementia Complex July 2015 Phase 4
NCT00985543 Kirby Institute Acquired Immunodeficiency Syndrome October 2009 Phase 1
NCT01810887 Janssen Pharmaceutical K.K. Healthy May 2008 Phase 4
NCT00885495 University of Cincinnati HIV Infections January 2009 Phase 1|Phase 2
NCT01047995 St Stephens Aids Trust HIV Infections June 2009 Phase 1
NCT00621166 The HIV Netherlands Australia Thailand Research Collaboration HIV Infections June 2008 Phase 2
NCT00477126 The HIV Netherlands Australia Thailand Research Collaboration|The Government Pharmaceutical Organization Healthy January 2007 Phase 1
NCT01172535 National Institute of Allergy and Infectious Diseases (NIAID) HIV November 2010 Phase 2|Phase 3
NCT02034838 Ottawa Hospital Research Institute|Bristol-Myers Squibb HIV Infection January 2014 Phase 1
NCT01237444 Pedro Cahn|Abbott|The Huesped Foundation HIV Infection December 2010 Phase 3
NCT01700790 University of Miami|Oswaldo Cruz Foundation AIDS|Tuberculosis January 2016 Phase 4
NCT01581853 Daniel Podzamczer|Hospital Universitari de Bellvitge HIV May 2012 Phase 4
NCT02348177 Drugs for Neglected Diseases|University of Cape Town|Medecins Sans Frontieres, Netherlands|French Development Agency|UBS Optimus Foundation Acquired Immunodeficiency Syndrome|Tuberculosis January 2013 Phase 4
NCT01002898 Bamrasnaradura Infectious Diseases Institute HIV April 2007 Phase 3
NCT01009437 Masonic Cancer Center, University of Minnesota|Susan G. Komen Breast Cancer Foundation Breast Cancer May 2010 Phase 1|Phase 2
NCT01258439 St Vincent's Hospital, Sydney|Merck Sharp & Dohme Corp. HIV|Cardiovascular Disease November 2010 Phase 4
NCT01695954 New York University School of Medicine|Bellevue/NYU AIDS Clinical Trials Unit|Kowa Pharmaceuticals America, Inc.|University at Buffalo Hyperlipidemia|HIV May 2012 Phase 1
NCT00855413 University of North Carolina, Chapel Hill|Janssen Pharmaceuticals Acute HIV Infection|HIV Infections March 2009 Phase 4
NCT02527707 Eiger BioPharmaceuticals|Hannover Medical School Chronic Delta Hepatitis September 2015 Phase 2
NCT02219503 AbbVie Chronic Hepatitis C Infection|Compensated Cirrhosis September 2014 Phase 3
NCT01660477 Astellas Pharma Global Development, Inc.|Basilea Pharmaceutica International Ltd|Astellas Pharma Inc Pharmacokinetics of Isavuconazole|Pharmacokinetics of Lopinavir/Ritonavir|Healthy Volunteers June 2012 Phase 1
NCT00622206 The HIV Netherlands Australia Thailand Research Collaboration HIV Infections January 2008 Phase 1|Phase 2
NCT00752037 Saint Michael's Medical Center|Abbott HIV Infections September 2008 Phase 4
NCT02183441 Boehringer Ingelheim Healthy April 2008 Phase 1
NCT00474201 National Institutes of Health Clinical Center (CC) Healthy Volunteers May 2007
NCT01891851 Tibotec Pharmaceuticals, Ireland Healthy October 2007 Phase 1
NCT01139905 The HIV Netherlands Australia Thailand Research Collaboration|Chulalongkorn University|UMC St. Radboud, Nijmegen, The Netherlands HIV-1 Infections April 2010 Phase 2
NCT03214159 First Affiliated Hospital of Zhejiang University|Ascletis Pharmaceutical Co., Ltd. Healthy Volunteer July 11, 2017 Phase 1
NCT01335698 Bristol-Myers Squibb HIV May 27, 2011 Phase 3
NCT00983515 Mutual Pharmaceutical Company, Inc. Pharmacokinetics July 2008 Phase 1
NCT00919854 Tibotec Pharmaceuticals, Ireland|Tibotec Pharmaceutical Limited Human Immunodeficiency Virus 1 September 2009 Phase 2
NCT01599364 Catholic University of the Sacred Heart Human Immunodeficiency Virus April 2014 Phase 4
NCT01606722 Hospitales Universitarios Virgen del Rocío HIV-infection January 2010
NCT01423812 Ruth M. Rothstein CORE Center|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA HIV January 2012 Phase 4
NCT01346800 University Hospital, Geneva Healthy Volunteers February 2011 Phase 1
NCT01672983 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection July 2012 Phase 2
NCT01194856 The Cleveland Clinic|National Institute of Allergy and Infectious Diseases (NIAID)|Case Western Reserve University|Bristol-Myers Squibb HIV Infection|Mitochondrial Dysfunction October 2010 Phase 4
NCT00765271 St Stephens Aids Trust HIV May 2008 Phase 1
NCT00611039 Germans Trias i Pujol Hospital HIV Infections February 2008 Phase 4
NCT00767117 Tibotec Pharmaceuticals, Ireland HIV September 2008 Phase 1
NCT01702090 Janssen-Cilag Ltd. HIV-1 February 2012 Phase 4
NCT01691794 Bristol-Myers Squibb HIV, Pediatric November 2012 Phase 4
NCT01531647 Hoffmann-La Roche Healthy Volunteer January 2012 Phase 1
NCT01541085 Janssen-Cilag S.p.A. Human Immunodeficiency Virus; HIV December 2011 Phase 4
NCT00993148 Northwestern University|Pfizer|Tibotec, Inc HIV-1 Infection|HIV Infections May 2010 Phase 2
NCT00981318 Rodwick, Barry M., M.D.|Abbott HIV Infections|Acquired Immunodeficiency Syndrome December 2009 Phase 4
NCT02845843 King Abdullah International Medical Research Center Middle East Respiratory Syndrome Coronavirus (MERS-CoV) July 2016 Phase 2|Phase 3
NCT02430194 Eiger BioPharmaceuticals|Ankara University Chronic Hepatitis D Infection December 2014 Phase 2
NCT00619944 Makerere University|University of Liverpool HIV Infections February 2008 Phase 4
NCT00802334 The HIV Netherlands Australia Thailand Research Collaboration|The Government Pharmaceutical Organization HIV January 2008 Phase 2
NCT02806362 AbbVie Chronic Hepatitis C Virus September 2016 Phase 3
NCT02159599 Fundacion SEIMC-GESIDA|Janssen, LP HIV Infection July 2014 Phase 4
NCT01511809 Ospedale San Raffaele|Bristol-Myers Squibb HIV-1 Infection September 2010 Phase 3
NCT01095094 Case Comprehensive Cancer Center Brain Tumor|Anaplastic Astrocytoma|Anaplastic Ependymoma|Anaplastic Oligodendroglioma|Brain Stem Glioma|Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma|Mixed Glioma January 2009 Phase 2
NCT01099579 Bristol-Myers Squibb HIV Infections October 13, 2010 Phase 3
NCT00607958 Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA HIV Infections December 2007 Phase 4
NCT00105079 Hoffmann-La Roche HIV Infections April 2005 Phase 3
NCT02948283 City of Hope Medical Center|National Cancer Institute (NCI) Anemia|Fatigue|Fever|Lymphadenopathy|Lymphocytosis|Night Sweats|Recurrent Chronic Lymphocytic Leukemia|Recurrent Plasma Cell Myeloma|Refractory Chronic Lymphocytic Leukemia|Refractory Plasma Cell Myeloma|Splenomegaly|Thrombocytopenia|Weight Loss March 8, 2017
NCT02159352 Bristol-Myers Squibb Hepatitis C June 2014 Phase 1
NCT02968641 Eiger BioPharmaceuticals Chronic Delta Hepatitis March 2017 Phase 2
NCT01514968 Hoffmann-La Roche Healthy Volunteer December 2011 Phase 1
NCT00486330 Yale University|Boehringer Ingelheim HIV Infections May 2006
NCT00994344 Germans Trias i Pujol Hospital HIV Infections October 2009 Phase 4
NCT01073761 St Stephens Aids Trust HIV|HIV Infections April 2010 Phase 1
NCT01209065 ViiV Healthcare|GlaxoSmithKline Infections, Human Immunodeficiency Virus and Herpesviridae September 2010 Phase 1
NCT00855088 University of North Carolina, Chapel Hill|Tibotec Pharmaceutical Limited HIV/AIDS|HIV Infections July 2009 Phase 1
NCT01156389 Medicines for Malaria Venture|Shin Poong Pharmaceuticals Malaria July 2010 Phase 1
NCT02582632 AbbVie Hepatitis C Infection|Hepatitis C Virus November 2015 Phase 3
NCT02493855 AbbVie Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1a June 2015 Phase 2
NCT02511431 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) Hepatitis D July 21, 2015 Phase 2
NCT02244190 Boehringer Ingelheim Healthy April 2008 Phase 1
NCT00197639 Harvard School of Public Health|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infection September 2006
NCT02609659 AbbVie Chronic Hepatitis C Infection October 2015 Phase 3
NCT00909311 Abbott HCV Infection May 2009 Phase 1
NCT00379405 Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA HIV Infections June 2006 Phase 4
NCT00775606 Rush University Medical Center|University of Chicago|University of Illinois at Chicago|Ruth M. Rothstein CORE Center|Abbott|Gilead Sciences Acquired Immune Deficiency Syndrome October 2008 Phase 4
NCT01227590 University of California, San Francisco Drug Interactions|Human Immunodeficiency Virus February 2010 Phase 1
NCT01251848 Pfizer Pulmonary Arterial Hypertension January 2011 Phase 1
NCT00654147 Margaret A. Fischl, M.D.|University of Miami HIV Infections April 2008 Phase 2
NCT00476983 The HIV Netherlands Australia Thailand Research Collaboration Saquinavir/Ritonavir BID or Lopinavir/Ritonavir BID Phase 2|Phase 3
NCT00833482 Bristol-Myers Squibb Human Immunodeficiency Virus Type 1 (HIV-1)|HIV Infections September 2009 Phase 1
NCT00630734 University of Colorado, Denver|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA HIV Infections|Hyperlipidemia February 2008 Phase 4
NCT01588002 Hoffmann-La Roche Healthy Volunteer April 2012 Phase 1
NCT00743470 Abbott HIV|Tuberculosis August 2008 Phase 1
NCT00357604 Bristol-Myers Squibb HIV Infections July 2006 Phase 1
NCT00931281 Abbott HCV Infection June 2009 Phase 1
NCT00002366 Abbott Sarcoma, Kaposi|HIV Infections Phase 2
NCT01426958 Boehringer Ingelheim Healthy August 2011 Phase 1
NCT00830804 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV-1 Infections April 2009 Phase 2
NCT00358917 Abbott Human Immunodeficiency Virus Infections August 2006 Phase 3
NCT00357188 Bristol-Myers Squibb HIV Infections|Protease Inhibitor July 2006 Phase 1
NCT01308658 Tibotec Pharmaceuticals, Ireland Healthy January 2011 Phase 1
NCT01332227 Bristol-Myers Squibb HIV, Combination Therapy October 2011 Phase 4
NCT02435563 University Hospital, Geneva Healthy August 2014 Phase 2
NCT01458054 GlaxoSmithKline Hepatitis C September 27, 2011 Phase 1
NCT02251795 Boehringer Ingelheim Healthy August 2007 Phase 1
NCT02219477 AbbVie Chronic Hepatitis C|Decompensated Cirrhosis|Hepatitis C Virus November 24, 2014 Phase 3
NCT00435929 Hoffmann-La Roche HIV Infections September 2006 Phase 1
NCT00281606 California Collaborative Treatment Group|Abbott HIV Infection February 2006 Phase 4
NCT02476617 AbbVie Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1a June 2015 Phase 3
NCT00977301 Radboud University|GlaxoSmithKline HIV Infections November 2009 Phase 1
NCT00640263 French National Agency for Research on AIDS and Viral Hepatitis|European and Developing Countries Clinical Trials Partnership (EDCTP)|The Research Council of Norway|Swedish International Development Cooperation Agency (SIDA)|Université Montpellier|University of Bergen|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) HIV Infections December 2009 Phase 3
NCT01813552 Merck Sharp & Dohme Corp. Chronic Hepatitis C Infection February 2013 Phase 1
NCT00344123 Johns Hopkins University|Boehringer Ingelheim HIV Infections February 2007 Phase 1
NCT00632970 George Washington University HIV Infections February 2008 Phase 4
NCT02171754 Boehringer Ingelheim Healthy September 2009 Phase 1
NCT02253901 Boehringer Ingelheim Healthy March 2005 Phase 1
NCT00855335 Janssen Scientific Affairs, LLC HIV|HIV Infections|Pregnancy April 2009 Phase 3
NCT00242879 ViiV Healthcare Infection, Human Immunodeficiency Virus I|HIV-1 Infection August 2005 Phase 2
NCT00850044 Abbott HCV Infection February 2009 Phase 1
NCT01389544 Hoffmann-La Roche Healthy Volunteer June 2011 Phase 1
NCT00362726 Bristol-Myers Squibb HIV Infections September 2006 Phase 1
NCT00665951 Radboud University HIV Infections September 2008 Phase 1
NCT01592318 Hoffmann-La Roche Healthy Volunteer May 2012 Phase 1
NCT01076985 Abbott Human Immunodeficiency Virus December 2000
NCT00144170 Boehringer Ingelheim HIV Infections February 2003 Phase 3
NCT02256774 Boehringer Ingelheim Healthy October 2004 Phase 1
NCT01076972 Abbott Human Immunodeficiency Virus December 2000
NCT00002223 Abbott HIV Infections
NCT00004578 Abbott HIV Infections November 1997 Phase 1|Phase 2
NCT00002201 Abbott HIV Infections
NCT00038480 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections Phase 1
NCT01519336 Hoffmann-La Roche Healthy Volunteer February 2012 Phase 1
NCT01391013 Janssen-Cilag S.p.A. Human Immunodeficiency Virus 1 June 2009 Phase 2
NCT01140412 ViiV Healthcare|Pfizer Healthy July 2010 Phase 1
NCT01668147 Washington University School of Medicine Drug Effects August 2012
NCT00946595 French National Agency for Research on AIDS and Viral Hepatitis|Abbott|Gilead Sciences|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) HIV Infections November 2009 Phase 2|Phase 3
NCT00102986 National Institute of Allergy and Infectious Diseases (NIAID)|AIDS Clinical Trials Group HIV Infections October 2005
NCT00833378 GlaxoSmithKline Hepatitis C|Thrombocytopenia January 2009 Phase 1
NCT00886990 The HIV Netherlands Australia Thailand Research Collaboration|Ministry of Education, Thailand HIV Infection|HIV Infections October 2007
NCT02565888 Radboud University Hepatitis C|HIV November 2015 Phase 1
NCT02216422 AbbVie Chronic Hepatitis C Virus (HCV) Infection September 2014 Phase 3
NCT00420355 University of Oklahoma|Abbott HIV Infection April 2007 Phase 4
NCT00006591 Gathe, Joseph, M.D.|NIH AIDS Clinical Trials Information Service HIV Infections
NCT00623597 Hoffmann-La Roche HIV Infections June 2008 Phase 2
NCT00148785 Emory University HIV Infections July 2005 Phase 4
NCT02430181 Eiger BioPharmaceuticals Chronic Hepatitis D Infection November 2014 Phase 2
NCT02251145 Boehringer Ingelheim Healthy May 2002 Phase 1
NCT01896622 National Institutes of Health Clinical Center (CC)|National Institute of Allergy and Infectious Diseases (NIAID) HIV June 18, 2013 Phase 1
NCT01418274 Hoffmann-La Roche Healthy Volunteer August 2011 Phase 1
NCT00770042 VIVUS, Inc. Erectile Dysfunction October 2008 Phase 1
NCT01221298 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C|HCV|Chronic Hepatitis C Infection|Hepatitis C Genotype 1 October 2010 Phase 2
NCT00257621 ViiV Healthcare Infection, Human Immunodeficiency Virus I|HIV Infection October 2004 Phase 2
NCT00450580 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus I|HIV-1 Infection March 2007 Phase 3
NCT00530920 Boehringer Ingelheim HIV Infections October 2007 Phase 2
NCT02399345 AbbVie Chronic Hepatitis C Virus (HCV Infection Genotype 1) March 2015 Phase 3
NCT03122132 Hepa C Hepatitis C Infection February 20, 2017
NCT00012519 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections Phase 1|Phase 2
NCT00381303 Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA HIV|Infectious November 2006 Phase 3
NCT00883935 GlaxoSmithKline|Shionogi Healthy Volunteer April 2009 Phase 1
NCT01306617 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection|Hepatitis C|Hepatitis C Virus February 2011 Phase 2
NCT02253875 Boehringer Ingelheim Healthy November 2005 Phase 1
NCT00357552 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections January 2008
NCT02063360 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus February 2014 Phase 1
NCT01392755 Hoffmann-La Roche Healthy Volunteer July 2011 Phase 1
NCT01290211 ViiV Healthcare|Pfizer Healthy April 2011 Phase 1
NCT00720590 National Heart, Lung, and Blood Institute (NHLBI) Endothelial Dysfunction November 2003
NCT00135343 Bristol-Myers Squibb HIV Infections April 2004 Phase 3
NCT01091649 Abbott Healthy February 2010 Phase 1
NCT00326716 Bristol-Myers Squibb HIV Infection June 2006 Phase 1
NCT00765154 St Stephens Aids Trust HIV October 2008 Phase 4
NCT00711009 Abbott|Merck Sharp & Dohme Corp. Human Immunodeficiency Virus Infection July 2008 Phase 3
NCT00005118 Merck Sharp & Dohme Corp.|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT00262522 Abbott Human Immunodeficiency Virus Infections November 2005 Phase 3
NCT00038636 Abbott HIV Infections September 2000 Phase 3
NCT01374802 Boehringer Ingelheim HIV Infections June 2011 Phase 1
NCT01165645 Mayo Clinic Hodgkin Lymphoma|Stage I Adult Hodgkin Lymphoma|Stage II Adult Hodgkin Lymphoma|Stage III Adult Hodgkin Lymphoma|Stage IV Adult Hodgkin Lymphoma November 2010
NCT00266058 University of California, San Francisco HIV Infections|Malaria December 2005 Phase 1
NCT00400738 The HIV Netherlands Australia Thailand Research Collaboration|Roche Pharma AG|International Antiviral Therapy Evaluation Center|Kirby Institute HIV Infections March 2004 Phase 2
NCT00089583 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus I July 2004 Phase 2
NCT00084019 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections July 2004
NCT02289482 GlaxoSmithKline Infection, Human Immunodeficiency Virus November 17, 2014 Phase 1
NCT00578825 Hospital Authority, Hong Kong Severe Acute Respiratory Syndrome
NCT00038519 Abbott HIV Infections April 2001 Phase 2|Phase 3
NCT00337467 Bristol-Myers Squibb Human Immunodeficiency Virus (HIV) Infections June 2006 Phase 3
NCT00867152 ViiV Healthcare|Shionogi Healthy Volunteer April 2009 Phase 1
NCT00004580 Abbott HIV Infections Phase 1
NCT01592305 Hoffmann-La Roche Healthy Volunteer May 2012 Phase 1
NCT00242216 The University of Texas Health Science Center, Houston HIV Infections May 2004 Phase 4
NCT00159224 The Huesped Foundation|Abbott HIV Infections April 2005 Phase 4
NCT00004582 ViRx|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT01449929 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus October 31, 2011 Phase 3
NCT00887120 The HIV Netherlands Australia Thailand Research Collaboration|Ministry of Education, Thailand HIV Infections April 2007 Phase 2
NCT00234975 AbbVie (prior sponsor, Abbott)|AbbVie HIV Infection October 2002 Phase 4
NCT00000952 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections Phase 1
NCT02253927 Boehringer Ingelheim Healthy May 2006 Phase 1
NCT00838162 Tibotec Pharmaceuticals, Ireland Human Immunodeficiency Virus Type 1 June 2009 Phase 2
NCT00552240 Boehringer Ingelheim HIV Infections September 2007 Phase 4
NCT02245451 Boehringer Ingelheim Healthy January 2005 Phase 1
NCT00524368 Tibotec Pharmaceuticals, Ireland Human Immunodeficiency Virus - Type 1 October 2007 Phase 3
NCT01013987 The Huesped Foundation|Pfizer HIV-1 Adults Patients|AIDS|Triple Class Failure February 2010 Phase 4
NCT02253836 Boehringer Ingelheim Healthy January 2005 Phase 1
NCT02487199 AbbVie HCV|Genotype 1a|Genotype 4|Chronic Kidney Disease|Hepatitis C|pegIFN|IFN September 2015 Phase 3
NCT00084058 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections Phase 1|Phase 2
NCT01345630 ViiV Healthcare|Pfizer HIV-1 September 2011 Phase 3
NCT03019991 Ascletis Pharmaceuticals Co., Ltd. Healthy October 2015 Phase 1
NCT00528060 French National Agency for Research on AIDS and Viral Hepatitis|Bristol-Myers Squibb|Gilead Sciences HIV Infections January 2008 Phase 2
NCT00001133 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 1
NCT00000898 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections
NCT00355524 Tibotec Pharmaceuticals, Ireland HIV-1|HIV Infections June 2006 Phase 2
NCT01714154 Hoffmann-La Roche Healthy Volunteer November 2012 Phase 1
NCT00344487 University of Maryland HIV December 2005
NCT00411996 The HIV Netherlands Australia Thailand Research Collaboration HIV Infections|Tuberculosis December 2006 Phase 1|Phase 2
NCT02253862 Boehringer Ingelheim Healthy December 2005 Phase 1
NCT02442284 AbbVie Chronic Hepatitis C|Cirrhosis|Hepatitis C Virus May 2015 Phase 3
NCT00025727 GlaxoSmithKline|NIH AIDS Clinical Trials Information Service HIV Infections May 2001 Phase 3
NCT02251158 Boehringer Ingelheim Healthy October 2003 Phase 1
NCT02581202 AbbVie HIV-1 Infection December 21, 2015
NCT00810108 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|American Association of Colleges of Pharmacy HIV/AIDS Treatment|HIV Infections June 2006 Phase 4
NCT02289495 GlaxoSmithKline Infection, Human Immunodeficiency Virus November 18, 2014 Phase 1
NCT01148004 National Institutes of Health Clinical Center (CC) HIV|Fenofibrate|Protease Inhibitors|Hypertriglyceridemia|Glucuronosyltransferase May 13, 2010 Phase 1
NCT00460746 Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA HIV May 2007 Phase 3
NCT00438152 Royal Free Hampstead NHS Trust|Roche Pharma AG HIV Infections September 2006 Phase 4
NCT02257021 Boehringer Ingelheim Healthy February 2005 Phase 1
NCT03067883 Ain Shams University Chronic Hepatitis c November 9, 2016 Phase 2
NCT00637637 Oncology Institute of Southern Switzerland|National Cancer Institute (NCI) Cancer September 2007 Phase 2
NCT01231685 McGill University Health Center|Merck Sharp & Dohme Corp.|CIHR Canadian HIV Trials Network HIV|Hepatitis C|Liver Fibrosis December 2011 Phase 2
NCT02265237 AbbVie Hepatitis C Virus October 28, 2014 Phase 3
NCT00534352 Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA HIV-1 Infection January 2008 Phase 2
NCT00001075 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections
NCT00196625 French National Agency for Research on AIDS and Viral Hepatitis HIV Infections November 2000 Phase 2
NCT00000888 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections|Pregnancy Phase 1
NCT01106586 Gilead Sciences HIV|HIV Infections April 2010 Phase 3
NCT01772940 Centre Hospitalier Universitaire Saint Pierre|University Hospital of Liege|Ministry of Public Health, Democratic Republic of the Congo|Pierre and Marie Curie University|University Paris 7 - Denis Diderot|Gilead Sciences|Abbott HIV-1 Infection December 2008 Phase 4
NCT02226978 Boehringer Ingelheim Healthy February 2007 Phase 1
NCT00389402 International Antiviral Therapy Evaluation Center|Hoffmann-La Roche|Gilead Sciences HIV Infections July 2006 Phase 4
NCT01483742 Hoffmann-La Roche Hepatitis C, Chronic April 2012 Phase 2
NCT02249416 Boehringer Ingelheim Healthy November 2001 Phase 1
NCT00043966 Abbott HIV Infections July 2002 Phase 3
NCT01638650 Hoffmann-La Roche HIV Infections January 2012 Phase 1
NCT01375881 Janssen-Cilag S.p.A. HIV Infections June 2009 Phase 4
NCT00571961 Yale University|Abbott HIV Infections January 2007
NCT01331850 Hoffmann-La Roche Hepatitis C, Chronic May 2011 Phase 2
NCT01057433 Kowa Research Institute, Inc. Healthy Volunteers January 2010 Phase 4
NCT01448707 Janssen-Cilag International NV Human Immunodeficiency Virus (HIV) Infections|Acquired Immunodeficiency Syndrome (AIDS) Virus March 2012 Phase 3
NCT00335270 Duke University|GlaxoSmithKline HIV March 2006 Phase 4
NCT00038532 Abbott HIV Infections April 2001 Phase 2
NCT01900106 University of Modena and Reggio Emilia HIV Infection July 2013 Phase 3
NCT01199939 Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA Human Immunodeficiency Virus (HIV) May 2010 Phase 2
NCT00001688 National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) HIV Infection January 1998 Phase 2
NCT01591850 Hoffmann-La Roche Healthy Volunteer September 2011 Phase 1
NCT01281813 Janssen Sciences Ireland UC HIV-1 Infections August 2011 Phase 3
NCT00000859 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections
NCT00544128 International Medical Center of Japan|Ministry of Health, Labour and Welfare, Japan HIV Infections October 2007 Phase 4
NCT02369965 Frontier Biotechnologies Co., Ltd. HIV Infections|AIDS January 2014 Phase 3
NCT02542852 Castagna Antonella|Bristol-Myers Squibb|ViiV Healthcare|Ospedale San Raffaele HIV-1 Infection September 2015 Phase 2
NCT02253914 Boehringer Ingelheim Healthy February 2004 Phase 1
NCT00122577 French National Agency for Research on AIDS and Viral Hepatitis|Bristol-Myers Squibb|Gilead Sciences HIV Infections March 2002 Phase 2
NCT01422369 Kowa Research Institute, Inc. Healthy April 2011 Phase 4
NCT02251119 Boehringer Ingelheim Healthy July 2002 Phase 1
NCT00140751 Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba|Abbott HIV Infections October 2005 Phase 3
NCT00764465 Garden State Infectious Disease Associates, PA|GlaxoSmithKline Healthy October 2008 Phase 2
NCT02207088 AbbVie Chronic Hepatitis C|Hepatitis C Virus|Compensated Cirrhosis|Severe Renal Impairment|End-stage Renal Disease September 2014 Phase 3
NCT03020082 Ascletis Pharmaceuticals Co., Ltd. Chronic Hepatitis C June 2016 Phase 3
NCT00440947 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus I|HIV Infection March 2007 Phase 3
NCT02442271 AbbVie Chronic Hepatitis C Infection April 2015 Phase 3
NCT00035932 Bristol-Myers Squibb HIV Infections November 2001 Phase 3
NCT02256826 Boehringer Ingelheim Healthy April 2005 Phase 1
NCT02253797 Boehringer Ingelheim Healthy July 2003 Phase 1
NCT00144287 Boehringer Ingelheim HIV Infections May 2004 Phase 3
NCT02770508 The Huesped Foundation|Ministry of Science and Technology,Argentine|National AIDS and STD programme,Argentine|Richmond Laboratories HIV-1 Infection November 2015 Phase 4
NCT01278134 Hoffmann-La Roche Hepatitis C, Chronic February 2011 Phase 2
NCT00028366 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections
NCT00915655 Tibotec Pharmaceuticals, Ireland|Tibotec Pharmaceutical Limited HIV-1 Infection July 2009 Phase 2
NCT01105611 St. James's Hospital, Ireland HIV Infections|Hepatitis C August 2010 Phase 4
NCT01225705 University Hospital, Bonn|Dr. Axel Baumgarten, Berlin|Dr. Christoph Stephan, Frankfurt/M|Dr. Stefan Esser, Essen|Dr. Keikawus Arastéh, Berlin|Prof. Dr. Hans-Jürgen Stellbrink, Hamburg|Dr. Thomas Lutz, Frankfurt/M|Dr. Jörg Gölz , Berlin HIV|Hepatitis C October 2010 Phase 4
NCT03020004 Ascletis Pharmaceuticals Co., Ltd. Chronic Hepatitis C January 2016 Phase 2
NCT01232127 Bristol-Myers Squibb HIV February 2011 Phase 4
NCT00357240 Bristol-Myers Squibb HIV Infections June 2006 Phase 1
NCT01736761 St Stephens Aids Trust HIV December 2012 Phase 4
NCT03020134 Ascletis Pharmaceuticals Co., Ltd. Healthy July 2016 Phase 1
NCT01464827 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C|Hepatitis C (HCV)|Hepatitis C Genotype 1 October 2011 Phase 2
NCT00125983 National Institute of Allergy and Infectious Diseases (NIAID)|AIDS Clinical Trials Group HIV Infections|Pregnancy Phase 2
NCT00002451 Merck Sharp & Dohme Corp.|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT01749150 Hoffmann-La Roche Hepatitis C, Chronic April 2013 Phase 2
NCT01274780 Juan A. Arnaiz|Hospital Clinic of Barcelona HIV-1 May 2011 Phase 4
NCT00006397 PPD|NIH AIDS Clinical Trials Information Service HIV Infections August 2000 Phase 3
NCT00775125 Tibotec BVBA Hepatitis C|Telaprevir|HIV June 2008 Phase 1
NCT00043953 Abbott HIV Infections August 2002 Phase 2
NCT00384904 Bristol-Myers Squibb HIV Infections December 2006 Phase 4
NCT01068873 Temple University|Abbott|Pfizer HIV Infections April 2010 Phase 4
NCT01825980 Novartis Pharmaceuticals|Novartis Hepatitis C March 2013 Phase 1|Phase 2
NCT00043888 GlaxoSmithKline HIV Infections January 2002 Phase 3
NCT00000920 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections|Pregnancy Phase 1
NCT02251223 Boehringer Ingelheim HIV Infections February 2001 Phase 1|Phase 2
NCT02138084 Bristol-Myers Squibb HIV/AIDS May 2014 Phase 1
NCT01628094 Hoffmann-La Roche Hepatitis C, Chronic June 2012 Phase 2
NCT01307488 Fundacion SEIMC-GESIDA|Bristol-Myers Squibb HIV Infection September 2011 Phase 4
NCT00564772 Allina Hospitals and Clinics Healthy November 2007 Phase 4
NCT00531557 St Stephens Aids Trust HIV Infections September 2007 Phase 4
NCT00075231 Abbott HIV Infections December 2003 Phase 2
NCT01083810 Abbott Human Immunodeficiency Virus June 2001
NCT00365339 Bristol-Myers Squibb HIV Infections April 2006 Phase 1
NCT02321384 Hoffmann-La Roche Healthy Volunteer December 15, 2014 Phase 1
NCT02253953 Boehringer Ingelheim Healthy November 2002 Phase 1
NCT00162149 Bristol-Myers Squibb HIV Infections October 2005 Phase 1
NCT00865007 Fundacion SEIMC-GESIDA|Abbott HIV Infection|Lipodystrophy|HIV Infections December 2008 Phase 4
NCT00009061 Glaxo Wellcome|NIH AIDS Clinical Trials Information Service HIV Infections November 2000 Phase 3
NCT00976950 Boehringer Ingelheim HIV Infections September 2009
NCT01935830 Washington University School of Medicine Healthy Volunteers August 2013 Early Phase 1
NCT00046033 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00063804 National Institute of Allergy and Infectious Diseases (NIAID)|AIDS Clinical Trials Group HIV Infections Phase 1
NCT01602822 Kenneth H. Mayer, MD|Bristol-Myers Squibb|Gilead Sciences|Abbott|Fenway Community Health HIV February 2012 Phase 4
NCT01185860 Hoffmann-La Roche Hepatitis C, Chronic August 2009 Phase 1
NCT01458535 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C Virus September 2011 Phase 2
NCT02245269 Boehringer Ingelheim Healthy July 2003 Phase 1
NCT00614991 Garden State Infectious Disease Associates, PA|GlaxoSmithKline Healthy January 2008
NCT02239835 Boehringer Ingelheim HIV Infections December 1999 Phase 2
NCT02275780 Merck Sharp & Dohme Corp. HIV-1 December 1, 2014 Phase 3
NCT00421551 French National Agency for Research on AIDS and Viral Hepatitis|Tibotec Pharmaceutical Limited|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) HIV Infections March 2007 Phase 3
NCT01398293 Hoffmann-La Roche Healthy Volunteer August 2011 Phase 1
NCT00931463 Kirby Institute|Merck Sharp & Dohme Corp.|Abbott|amfAR, The Foundation for AIDS Research HIV Infections September 2009 Phase 4
NCT02238314 Boehringer Ingelheim HIV Infections January 1999 Phase 2
NCT02243553 Boehringer Ingelheim Healthy January 2006 Phase 1
NCT01571414 National Institute of Allergy and Infectious Diseases (NIAID) Tuberculosis May 2012 Phase 1
NCT01189695 Bamrasnaradura Infectious Diseases Institute|Department of Disease Control, Thailand HIV|AIDS|Lopinavir|Treatment Failure December 2010 Phase 4
NCT02950870 University of Modena and Reggio Emilia Chronic Hepatitis, C Virus December 2016 Phase 4
NCT00920088 GlaxoSmithKline Healthy Subjects|Infection, Human Immunodeficiency Virus June 2009 Phase 1
NCT00040664 ViiV Healthcare HIV Infection July 2002 Phase 2
NCT01902186 Giovanni Di Perri|University of Turin, Italy|University of Milan HIV Infection|Osteopenia September 2014 Phase 4
NCT00531999 St Stephens Aids Trust HIV Infections October 2007 Phase 1
NCT00002239 Hoffmann-La Roche|Trimeris HIV Infections May 1999 Phase 2
NCT00096850 National Institute of Allergy and Infectious Diseases (NIAID)|AIDS Clinical Trials Group HIV Infections|Tuberculosis
NCT00145561 Radboud University|Hoffmann-La Roche HIV Infections August 2005 Phase 1|Phase 2
NCT00234923 Abbott HIV Infection August 2003 Phase 3
NCT01852604 Merck Sharp & Dohme Corp.|Janssen Research & Development, LLC Chronic Hepatitis C Virus March 2013 Phase 2
NCT00056641 Boehringer Ingelheim HIV Infections January 2003 Phase 2
NCT00028301 Bristol-Myers Squibb HIV Infections February 2001 Phase 3
NCT00885482 Catholic University of the Sacred Heart HIV Infections May 2009 Phase 4
NCT01088516 University of Zambia|University of Toronto|Abbott HIV December 2008 Phase 4
NCT00531206 Boehringer Ingelheim HIV Infections August 2006
NCT01074008 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C|HCV|Chronic Hepatitis C Infection|Hepatitis C Genotype 1 March 2010 Phase 2
NCT00054717 Boehringer Ingelheim HIV Infections January 2003 Phase 3
NCT00646776 Bristol-Myers Squibb Antivirals/HIV April 2008 Phase 1
NCT02226991 Boehringer Ingelheim Healthy April 2006 Phase 1
NCT00114933 Arribas, Jose R., M.D.|Pulido, Federico, M.D.|Abbott HIV Infection January 2005 Phase 4
NCT01802918 GlaxoSmithKline Infection, Human Immunodeficiency Virus February 18, 2013 Phase 1
NCT03020095 Ascletis Pharmaceuticals Co., Ltd. Chronic Hepatitis C August 2015 Phase 2
NCT01164488 Hoffmann-La Roche Healthy Volunteer July 2010 Phase 1
NCT01185873 Hoffmann-La Roche Healthy Volunteer February 2011 Phase 1
NCT02064842 Janssen R&D Ireland Healthy February 2014 Phase 1
NCT02251132 Boehringer Ingelheim Healthy October 2000 Phase 1
NCT02253888 Boehringer Ingelheim Healthy May 2005 Phase 1
NCT00224445 Gilead Sciences HIV Infections September 2005 Phase 4
NCT01483729 Hoffmann-La Roche Healthy Volunteer December 2011 Phase 1
NCT00697892 Fran Aweeka|University of California, San Francisco HIV Infections|Malaria July 2005 Phase 1
NCT00525733 Rockefeller University|Aaron Diamond AIDS Research Center|Merck Sharp & Dohme Corp.|Pfizer HIV Infections October 2007
NCT00143689 University of British Columbia|Abbott|Boehringer Ingelheim|CIHR Canadian HIV Trials Network HIV|Mitochondrial Toxicity April 2002 Phase 4
NCT02116660 Merck Sharp & Dohme Corp. HIV Infections September 3, 2014 Phase 2
NCT00002361 Merck Sharp & Dohme Corp.|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT02068222 AbbVie Chronic Hepatitis C|Hepatitis C Virus April 2014 Phase 2
NCT01935674 Juan A. Arnaiz|Hospital Clinic of Barcelona HIV|Hypercholesterolaemia September 2013 Phase 4
NCT00424814 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Abbott HIV Infections March 2007 Phase 2|Phase 3
NCT02245438 Boehringer Ingelheim Healthy May 2002 Phase 1
NCT01010399 Felizarta, Franco, M.D.|GlaxoSmithKline Hypertriglyceridemia|HIV Infection September 2009 Phase 4
NCT00120393 Bristol-Myers Squibb HIV Infections January 2004 Phase 3
NCT01166477 Sociedad Andaluza de Enfermedades Infecciosas HIV Infection January 2010 Phase 4
NCT00001766 National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) HIV Infection August 1998 Phase 1
NCT01876966 Janssen Pharmaceutica N.V., Belgium HIV March 2011 Phase 1
NCT02198443 Fundacion Clinic per a la Recerca Biomédica HIV June 6, 2015 Phase 4
NCT02259855 Boehringer Ingelheim Hepatic Insufficiency January 2006 Phase 1
NCT00234910 Abbott HIV Infection January 2005 Phase 3
NCT00038220 Abbott HIV Infections July 2000 Phase 2
NCT00004581 Abbott HIV Infections Phase 3
NCT02634008 Kirby Institute|AbbVie Hepatitis C, Acute June 2016 Phase 3
NCT00086359 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections July 2004 Phase 3
NCT02504099 AbbVie Chronic Hepatitis C Infection July 2015 Phase 3
NCT02251171 Boehringer Ingelheim Healthy August 2003 Phase 1
NCT00005017 Glaxo Wellcome|NIH AIDS Clinical Trials Information Service HIV Infections Phase 4
NCT00084149 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections February 2004 Phase 2
NCT01323257 Tibotec Pharmaceuticals, Ireland Hepatitis C Virus March 2011 Phase 1
NCT00444379 University of California, San Francisco|National Institutes of Health (NIH)|Gilead Sciences|Abbott|Merck Sharp & Dohme Corp. Kaposi's Sarcoma|HIV Infections April 2007 Phase 4
NCT01351740 University of British Columbia HIV Infection July 2011 Phase 4
NCT00270296 National Institute of Allergy and Infectious Diseases (NIAID)|Harvard School of Public Health HIV Infections June 2006 Phase 2
NCT01869634 University of California, Davis Human Immunodeficiency Virus Infection June 2013 Phase 4
NCT00661349 Germans Trias i Pujol Hospital HIV Infections February 2008 Phase 4
NCT00144833 GlaxoSmithKline HIV-1 March 2005 Phase 3
NCT01910402 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus August 1, 2013 Phase 3
NCT01220947 Hoffmann-La Roche Hepatitis C, Chronic November 2010 Phase 2
NCT00002241 Merck Sharp & Dohme Corp.|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT00085943 GlaxoSmithKline HIV Infection|Infection, Human Immunodeficiency Virus May 2004 Phase 3
NCT02386098 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus July 8, 2015 Phase 2
NCT02229760 Boehringer Ingelheim HIV Infections August 2006 Phase 1|Phase 2
NCT00517192 Boehringer Ingelheim HIV Infections September 2007 Phase 3
NCT00118898 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections September 2005 Phase 3
NCT00525239 National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) HIV Infections March 2004
NCT00651066 French National Agency for Research on AIDS and Viral Hepatitis|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) HIV Infections|Tuberculosis June 2010 Phase 2
NCT02023450 The Third Xiangya Hospital of Central South University|Xiangya Hospital of Central South University Pulmonary Arterial Hypertension December 2013 Early Phase 1
NCT01368783 Asan Medical Center|Bristol-Myers Squibb Atazanavir June 2011 Phase 1
NCT01654211 Hoffmann-La Roche Healthy Volunteer July 2012 Phase 1
NCT00513513 Tibotec Pharmaceuticals, Ireland HIV Infections September 2006 Phase 2
NCT00817765 Radboud University|GlaxoSmithKline HIV Infection|Fungal Infection January 2009 Phase 1
NCT00679926 Oklahoma State University Center for Health Sciences|Abbott HIV Infections May 2008 Phase 4
NCT01966822 Fundacio Lluita Contra la SIDA HIV-1 Infection January 2014 Phase 3
NCT01620944 Bristol-Myers Squibb HIV July 2012 Phase 3
NCT00121017 Abbott HIV Infection|Hepatitis C Phase 2
NCT00759070 Juan A. Arnaiz|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Germans Trias i Pujol Hospital|Hospital Universitari Joan XXIII de Tarragona.|Hospitales Universitarios Virgen del Rocío|Hospital Clinic of Barcelona HIV Infections September 2008 Phase 4
NCT00802074 Garden State Infectious Disease Associates, PA|GlaxoSmithKline Healthy December 2008
NCT00097799 Boehringer Ingelheim HIV Infections December 2004
NCT00426296 Clinical Alliance for Research & Education - Infectious Diseases, LLC.|GlaxoSmithKline HIV Infections|Lipodystrophy August 2006 Phase 4
NCT02486406 AbbVie Chronic Hepatitis C Infection October 28, 2015 Phase 3
NCT00413153 Massachusetts General Hospital|Bristol-Myers Squibb HIV Infections May 2006
NCT01605084 Bristol-Myers Squibb HIV June 2012 Phase 3
NCT00834457 Parirenyatwa Hospital|University of Colorado, Denver|GlaxoSmithKline|Abbott AIDS-related Kaposi's Sarcoma June 2007 Phase 2|Phase 3
NCT00071760 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus October 2003 Phase 2
NCT01009814 Bristol-Myers Squibb HIV-1 Infections November 2009 Phase 2
NCT01118871 Imperial College London HIV|HIV Infections May 2010 Phase 4
NCT02203461 Technische Universität München|Gilead Sciences|MUC Research GmbH Insulin Resistance July 2014 Phase 1
NCT00135395 Bristol-Myers Squibb HIV Infections May 2004 Phase 3
NCT00409591 Institut de Recherche pour le Developpement|Harvard School of Public Health|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections|Pregnancy July 2008 Phase 3
NCT00928187 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Gilead Sciences|Janssen Pharmaceutica HIV|HIV Infections November 2009 Phase 3
NCT01125696 Centers for Disease Control and Prevention|National Center for AIDS/STD Control and Prevention, China CDC HIV|Hepatitis B May 2012 Phase 2
NCT00001968 National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) Acquired Immunodeficiency Syndrome|HIV Infections January 2000 Phase 1
NCT01579019 Hoffmann-La Roche Hepatitis C, Chronic July 2012 Phase 2
NCT00335322 Kirby Institute|The University of New South Wales Human Immunodeficiency Virus (HIV) February 2007 Phase 4
NCT00023218 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections|Hepatitis C
NCT02150993 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) HIV-2 Infection January 26, 2016 Phase 2|Phase 3
NCT00001083 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT01394133 University of Alabama at Birmingham|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infected July 2011
NCT01516970 Janssen-Cilag G.m.b.H Human Immunodeficiency Virus (HIV) November 25, 2011 Phase 3
NCT00797745 Merck Sharp & Dohme Corp. Hepatitis C, Chronic November 2008 Phase 2
NCT00966160 University of Cologne Acquired Immunodeficiency Syndrome|HIV Infections January 1999 Phase 3
NCT01445223 Göteborg University HIV April 2004 Phase 4
NCT00004583 Abbott HIV Infections March 1999 Phase 3
NCT00532168 Juan A. Arnaiz|Hospital Clinic of Barcelona HIV Infections September 2007 Phase 4
NCT01818856 Hospitales Universitarios Virgen del Rocío|Bristol-Myers Squibb Hepatitis C, Chronic|HIV Infection December 2012 Phase 1
NCT00109590 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections June 2006 Phase 2
NCT00896051 Janssen R&D Ireland HIV Infections|Acquired Immunodeficiency Syndrome August 2009 Phase 2
NCT00207142 Bristol-Myers Squibb HIV Infections November 2005 Phase 4
NCT01033760 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|Gilead Sciences|Merck Sharp & Dohme Corp.|Pfizer|Janssen-Cilag Ltd. HIV-1 Infections April 2010 Phase 3
NCT00002448 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections October 1999 Phase 3
NCT00102778 ViiV Healthcare Infection, Human Immunodeficiency Virus I|HIV Infection December 2004 Phase 2
NCT00002447 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections October 1999 Phase 3
NCT01829802 Pedro Cahn|Merck Sharp & Dohme Corp.|The Huesped Foundation Chronic Infection With HIV May 2014 Phase 4
NCT00481182 GlaxoSmithKline Healthy Subjects February 2005 Phase 1
NCT03017872 Kirby Institute|UNITAID|National Health and Medical Research Council, Australia|ViiV Healthcare|Janssen Pharmaceutica HIV Infections July 2017 Phase 4
NCT00936793 National Institutes of Health Clinical Center (CC) HIV|Asthma July 6, 2009 Phase 1
NCT00869960 University of Alabama at Birmingham|National Institute of Allergy and Infectious Diseases (NIAID) Healthy March 2009 Phase 4
NCT00440271 Boehringer Ingelheim HIV Infections February 2007 Phase 3
NCT01192035 University of Aarhus|Aarhus University Hospital Skejby|Bandim Health Project|Ministry of Health, Guinea-Bissau|Abbott HIV-1 May 2011 Phase 4
NCT00000892 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections
NCT01759875 University of California, San Francisco Healthy January 2013 Phase 1
NCT00648999 AbbVie (prior sponsor, Abbott)|AbbVie Human Immunodeficiency Virus November 2003 Phase 4
NCT01343225 East Carolina University HIV May 2011 Phase 4
NCT00877591 University of California, San Francisco|State University of New York at Buffalo|University of Utah Opioid Dependency|HIV Infections April 2008 Phase 1
NCT02397096 Merck Sharp & Dohme Corp. HIV-1 Infection June 9, 2015 Phase 3
NCT01138605 Janssen Sciences Ireland UC HIV-1 Infections October 13, 2010 Phase 2
NCT02437110 National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC) Amyotrophic Lateral Sclerosis April 23, 2015 Phase 1
NCT01803074 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus April 2013 Phase 2
NCT02097381 University of Roma La Sapienza|Istituto Superiore di Sanità HIV Infection April 2010
NCT00386659 Hospital Clinic of Barcelona HIV Infection Phase 4
NCT00540137 Imperial College London|Boehringer Ingelheim HIV Infections July 2007 Phase 4
NCT01513122 Kirby Institute HIV February 2010 Phase 4
NCT00640887 French National Agency for Research on AIDS and Viral Hepatitis HIV Infections|Tuberculosis February 2009 Phase 2
NCT02249442 Boehringer Ingelheim Hepatic Insufficiency October 2003 Phase 1
NCT00393328 Bristol-Myers Squibb HIV Infections November 2006 Phase 1
NCT00355719 Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA|Hospital San Jaime de Calella HIV Infections January 2007 Phase 4
NCT00006604 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|International Maternal Pediatric Adolescent AIDS Clinical Trials Group HIV Infections November 2000 Phase 1|Phase 2
NCT00414518 University of Colorado, Denver|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections January 2007
NCT01400412 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV-1 Infection December 2011 Phase 2
NCT02786537 University of Florida|Patient-Centered Outcomes Research Institute|Merck Sharp & Dohme Corp.|AbbVie Chronic Hepatitis C June 2016 Phase 4
NCT02795754 GlaxoSmithKline Infection, Human Immunodeficiency Virus March 2016 Phase 1
NCT00866021 Fundacion SEIMC-GESIDA|Abbott HIV/HCV Co-infection|HIV Infections February 2008 Phase 4
NCT01332552 GlaxoSmithKline Hepatitis C January 14, 2011 Phase 1
NCT02404259 The HIV Netherlands Australia Thailand Research Collaboration|Chulalongkorn University|Khon Kaen University HIV June 2010
NCT00460382 French National Agency for Research on AIDS and Viral Hepatitis|Merck Sharp & Dohme Corp.|Janssen-Cilag Tibotec HIV Infections May 2007 Phase 2
NCT01003990 Bristol-Myers Squibb HIV October 2002 Phase 3
NCT00851799 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infection June 2009
NCT00084253 Bristol-Myers Squibb HIV Infections June 2004 Phase 4
NCT00757783 Tibotec, Inc|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA HIV October 2008 Phase 4
NCT00234962 Abbott HIV Infection August 2002 Phase 4
NCT01637558 University of Cape Town|Liverpool School of Tropical Medicine|Uppsala University|University of North Carolina Tuberculosis|HIV November 2012 Phase 4
NCT02707952 AbbVie Chronic Hepatitis C Virus|Hepatitis C Virus February 2016 Phase 3
NCT02253940 Boehringer Ingelheim Healthy October 2006 Phase 1
NCT01854762 Fundação Bahiana de Infectologia HIV|Pregnancy March 2015 Phase 2|Phase 3
NCT00162643 Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|National Council of Science and Technology, Mexico|Instituto Mexicano del Seguro Social Acquired Immunodeficiency Syndrome December 2004 Phase 4
NCT01146873 Columbia University|University of Witwatersrand, South Africa|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV/AIDS|HIV Infections July 2010 Phase 3
NCT00000940 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections May 1999 Phase 2
NCT01180075 University of North Carolina, Chapel Hill|National Institute of Allergy and Infectious Diseases (NIAID) Human Immunodeficiency Virus May 2010
NCT00004584 Bristol-Myers Squibb HIV Infections December 1999 Phase 2
NCT02253849 Boehringer Ingelheim Healthy November 2005 Phase 1
NCT00000906 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 1
NCT00027339 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00949234 University of California, Los Angeles|Los Angeles County Department of Public Health|AIDS Project Los Angeles|Los Angeles LGBT Center|OASIS Clinic HIV Transmission|HIV Infections March 2010 Phase 2
NCT00135356 Bristol-Myers Squibb HIV-Associated Lipodystrophy Syndrome July 2005 Phase 4
NCT02249130 Boehringer Ingelheim HIV Infections March 1999 Phase 2
NCT00878306 University of California, San Francisco|National Institute on Drug Abuse (NIDA) HIV Infections|Drug Abuse November 2008 Phase 1
NCT00605098 Oswaldo Cruz Foundation|Ministry of Health, Brazil HIV Infections|Pregnancy February 2008 Phase 4
NCT00677300 Dallas VA Medical Center|Merck Sharp & Dohme Corp.|Tibotec Pharmaceutical Limited HIV Infections January 2009 Phase 4
NCT01081158 Merck Sharp & Dohme Corp. Hepatitis C, Chronic July 2007 Phase 1
NCT01153269 Abbott Human Immunodeficiency Virus-Infection May 2001
NCT01066962 French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)|NEAT - European AIDS Treatment Network HIV Infections August 2010 Phase 3
NCT00885664 University of Cincinnati|Abbott|Gilead Sciences HIV Infections October 2005 Phase 4
NCT01724086 Janssen R&D Ireland Chronic Hepatitis C October 2012 Phase 2
NCT00090779 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Adult AIDS Clinical Trials Group HIV Infections January 2005 Phase 2
NCT00039975 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections|Cardiovascular Diseases|Hypertension Phase 1
NCT02251769 Boehringer Ingelheim Healthy August 2003 Phase 1
NCT00447902 Boehringer Ingelheim HIV Infections March 2007 Phase 3
NCT00050895 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 3
NCT01601626 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infection|Tuberculosis April 2013 Phase 2
NCT00443703 Merck Sharp & Dohme Corp. HIV Infection May 2007 Phase 3
NCT00164736 Centers for Disease Control and Prevention|University of North Carolina, Chapel Hill|Kamuzu Central Hospital, Lilongwe, Malawi HIV Infections March 2004 Phase 3
NCT02219672 Peking Union Medical College|Ministry of Science and Technology of the People´s Republic of China AIDS/HIV PROBLEM July 2014 Phase 3
NCT00768989 Bristol-Myers Squibb|Merck Sharp & Dohme Corp. HIV November 2008 Phase 2
NCT01565889 Gilead Sciences Hepatitis C|HIV March 2012 Phase 1|Phase 2
NCT00296504 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus November 2001 Phase 3
NCT02470650 Juan A. Arnaiz|Hospital Clinic of Barcelona Patient Compliance|Antiretroviral Therapy Intolerance June 2015 Phase 4
NCT00443729 Merck Sharp & Dohme Corp. HIV Infection May 2007 Phase 3
NCT00936195 French National Agency for Research on AIDS and Viral Hepatitis|Gilead Sciences|Merck Sharp & Dohme Corp.|GlaxoSmithKline|Abbott HIV Infection|Pregnancy|Breastfeeding|HIV Infections January 2010 Phase 3
NCT02489487 Viriom HIV-infection September 2014 Phase 1
NCT00342355 National Institutes of Health Clinical Center (CC) HIV January 2004 Phase 4
NCT00977756 International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections August 2002
NCT01903031 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV-1 Infection November 2014 Phase 2
NCT00135434 Bristol-Myers Squibb HIV Infections September 2004 Phase 1
NCT01563536 AbbVie (prior sponsor, Abbott)|AbbVie Chronic Hepatitis C Infection February 2012 Phase 2
NCT00122226 VU University Medical Center|Abbott|Boehringer Ingelheim HIV Infections|HIV-Associated Lipodystrophy Syndrome January 2003 Phase 4
NCT01154673 University of Toronto|St. Michael's Hospital, Toronto|Maple Leaf Medical Clinic Acute HIV Infection November 2011 Phase 2|Phase 3
NCT02194998 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections August 2015 Phase 2
NCT03070470 Food and Drug Administration (FDA)|Spaulding Clinical Research LLC Drug-induced QT Prolongation|Pharmacokinetics|Pharmacodynamics March 14, 2017 Phase 1
NCT00006152 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT01615601 Janssen Inc. Human Immunodeficiency Virus (HIV) October 2011 Phase 4
NCT01583439 Harvard School of Public Health|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections September 2012
NCT00005762 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections March 2001
NCT00016601 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections June 2001
NCT00099632 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections March 2006 Phase 2
NCT00000941 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 1
NCT02631473 St Stephens Aids Trust|University of Liverpool HIV November 2015 Phase 1
NCT01773070 AbbVie (prior sponsor, Abbott)|AbbVie Hepatitis C June 2013 Phase 3
NCT00006326 Agouron Pharmaceuticals|NIH AIDS Clinical Trials Information Service HIV Infections August 2000
NCT01352715 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV-1 Infection January 2012 Phase 3
NCT00000924 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections Phase 2
NCT02555943 Humanity & Healthy GI and Liver Centre|Beijing 302 Hospital|Nanfang Hospital of Southern Medical University Chronic Hepatitis C Infection|HBV Coinfection|Hepatitis B Reactivation February 2015 Phase 2|Phase 3
NCT00001087 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00006144 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections October 2000 Phase 2
NCT00000913 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00017992 Triangle Pharmaceuticals|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT00307502 Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA HIV Infections January 2005 Phase 1
NCT00120783 French National Agency for Research on AIDS and Viral Hepatitis HIV Infections February 2002 Phase 2
NCT00260078 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections February 2006 Phase 1|Phase 2
NCT02712801 National Center for Women and Children's Health, China CDC|National Center for AIDS/STD Control and Prevention, China CDC|Maternal and Child Health Hospital of Yunan Province|Maternal and Child Health Hospital of Sichuan Province|Maternal and Child Health Hospital of Guangxi Province|Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region|Guangdong Provincial Maternal and Child Health Hospital HIV/AIDS and Infections April 2016 Phase 4
NCT00028314 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections|Lipodystrophy|Wasting Disease March 2002
NCT01632891 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV-1 Infection|Pf Subclinical Parasitemia July 2013 Phase 1|Phase 2
NCT02195466 Boehringer Ingelheim Healthy June 2003 Phase 1
NCT00717067 ViiV Healthcare|Pfizer Human Immunodeficiency Virus (HIV) Infection July 2008 Phase 4
NCT00001108 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections Phase 1
NCT00000822 National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Immuno-US HIV Infections Phase 1
NCT02257008 Boehringer Ingelheim Healthy March 2003 Phase 1
NCT00051831 National Institute of Allergy and Infectious Diseases (NIAID)|AIDS Clinical Trials Group HIV Infections October 2003
NCT03194165 Assistance Publique - Hôpitaux de Paris Minor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed June 16, 2017
NCT00945282 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus October 2009 Phase 2
NCT00075907 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections July 2004 Phase 3
NCT00042289 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections March 2003 Phase 4
NCT00000914 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections
NCT00036452 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT01384734 Bristol-Myers Squibb Human Immunodeficiency Virus-1 July 2011 Phase 2
NCT00055120 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections|AIDS-Related Opportunistic Infections March 2003 Phase 4
NCT00811954 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb|Gilead Sciences|Merck Sharp & Dohme Corp.|Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA HIV Infection May 2009 Phase 3
NCT00573001 French National Agency for Research on AIDS and Viral Hepatitis|Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba|Gilead Sciences|Merck Sharp & Dohme Corp.|French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) HIV Infections July 2008 Phase 3
NCT00006578 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections
NCT00002374 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections Phase 3
NCT00002178 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections Phase 3
NCT00100646 The Wistar Institute HIV Infections March 2007
NCT00476606 The HIV Netherlands Australia Thailand Research Collaboration|Khon Kaen University HIV Infections March 2003
NCT00006339 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT02259868 Boehringer Ingelheim Healthy June 2005 Phase 1
NCT00001091 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections Phase 1
NCT02460133 Lisa Barrett|PEI Provincial Correction Centre|Nova Scotia Health Authority Hepatitis C Virus July 2015 Phase 4
NCT00719602 International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections|Malaria August 2009 Early Phase 1
NCT00307151 International Maternal Pediatric Adolescent AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections December 2005 Phase 2
NCT00122590 French National Agency for Research on AIDS and Viral Hepatitis|Hoffmann-La Roche HIV Infections July 2002
NCT00004855 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections
NCT00608569 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections March 2009
NCT00993031 University of California, San Francisco|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Malaria|HIV Infections December 2009 Phase 3
NCT02758509 Parc de Salut Mar Chronic Hepatitis C|Cirrhosis January 1, 2010
NCT00001058 National Institute of Allergy and Infectious Diseases (NIAID) Mycobacterium Avium-intracellulare Infection|HIV Infections Phase 2
NCT00000902 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 1
NCT00006154 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 3
NCT00014937 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections
NCT00034086 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections
NCT00537966 University of Zurich HIV Infections January 2002
NCT00003008 Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|AIDS Associated Malignancies Clinical Trials Consortium Sarcoma June 1997 Phase 2
NCT00234091 National Institute of Allergy and Infectious Diseases (NIAID)|Comprehensive International Program of Research on AIDS HIV Infections April 2006 Phase 3
NCT00089505 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections November 2006 Phase 3
NCT00255840 CIPRA SA|National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections July 2006
NCT01253538 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV April 2011
NCT01061151 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections March 2011
NCT02770378 University of Ulm|Reliable Cancer Therapies|Anticancer Fund, Belgium Glioblastoma November 2016 Phase 1
NCT00074581 National Institute of Allergy and Infectious Diseases (NIAID)|HIV Prevention Trials Network HIV Infections February 2005 Phase 3
NCT00158405 French National Agency for Research on AIDS and Viral Hepatitis|Bristol-Myers Squibb HIV Infections December 2002 Phase 3
NCT00427297 University of Washington|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections September 2007 Phase 3
NCT00002440 Glaxo Wellcome|NIH AIDS Clinical Trials Information Service HIV Infections Phase 2
NCT00100581 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections|Hepatitis C
NCT02333292 Valme University Hospital|Hospital del SAS de Jerez|Hospital General Universitario Elche|Hospital La Línea de la Concepción|Complexo Hospitalario Universitario de A Coruña|Hospital de Figueres|Hospital Universitario Puerto Real|Hospital Universitario Virgen de la Victoria|Hospital Universitario de Canarias|Hospital General Universitario de Alicante|Hospital Universitario Araba|Hospital Royo Vilanova|Hospital Universitario de Burgos|Complejo Hospitalario Universitario de Huelva|Hospital Universitario Reina Sofia|Hospital Universitario Virgen Macarena|Complexo Hospitalario Universitario de Vigo|Clinica Universidad de Navarra, Universidad de Navarra|Hospital Clinico Universitario San Cecilio|Hospital Universitario La Fe|Hospital General Universitario de Valencia|Hospital Universitario Infanta Leonor|Hospital Universitario de Gran Canaria|Hospital General Universitario Santa Lucía|Centro Penitenciario Alicante 1|Hospital Regional Universitario Carlos Haya|Hospital Virgen de la Luz|Hospital General Universitario de Castellón|Hospital Parc Taulí, Sabadell Chronic Hepatitis C Infection December 2014
NCT00002378 Hoffmann-La Roche|NIH AIDS Clinical Trials Information Service HIV Infections Phase 3
NCT00000891 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00000919 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections
NCT00000918 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections Phase 2
NCT00001119 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections October 1999
NCT00192660 Kirby Institute|St Vincent's Hospital, Sydney|National Heart, Lung, and Blood Institute (NHLBI) HIV-Associated Lipodystrophy Syndrome|Cardiovascular Disease February 2003 Phase 4
NCT00102206 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) HIV Infections Phase 2
NCT00102960 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections July 2005 Phase 3
NCT00080522 National Institute of Allergy and Infectious Diseases (NIAID) HIV Infections February 2005
NCT02187107 Tibotec Pharmaceuticals, Ireland HIV January 2005 Phase 2
NCT00445146 Gilead Sciences HIV Infections February 2007 Phase 2
NCT00110877 Tibotec Pharmaceuticals, Ireland HIV Infection April 2005 Phase 3
NCT00071097 Tibotec Pharmaceuticals, Ireland HIV Infections October 2003 Phase 2
NCT01907724 Merck Sharp & Dohme Corp.|Janssen Research & Development, LLC Hepatitis C, Chronic May 2013 Phase 1
NCT01077635 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus October 2008
NCT02253823 Boehringer Ingelheim Healthy December 2001 Phase 1
NCT02227238 ViiV Healthcare|GlaxoSmithKline Infection, Human Immunodeficiency Virus December 1, 2014 Phase 3
NCT02227017 Boehringer Ingelheim Healthy February 2006 Phase 1
NCT01475838 Gilead Sciences Acquired Immunodeficiency Syndrome|HIV Infections November 2011 Phase 3
NCT02652624 Gilead Sciences HIV-1 Infection February 1, 2016 Phase 3
NCT01705574 Gilead Sciences Acquired Immunodeficiency Syndrome|HIV Infections October 24, 2012 Phase 3
NCT01052883 Tibotec Pharmaceuticals, Ireland HIV Infections March 2010 Phase 1
NCT01108510 Gilead Sciences HIV|HIV Infections April 2010 Phase 3
NCT00892437 Gilead Sciences HIV-1 Infection May 2009 Phase 2
NCT00144105 Boehringer Ingelheim HIV Infections February 2004 Phase 2
NCT02251873 Boehringer Ingelheim Healthy September 2001 Phase 1
NCT00258557 Tibotec Pharmaceuticals, Ireland HIV September 2005 Phase 3
NCT00272779 Bristol-Myers Squibb HIV Infections November 2005 Phase 3
NCT00076999 Boehringer Ingelheim HIV Infections November 2003 Phase 1
NCT01252940 Gilead Sciences HIV-1 Infection November 2010 Phase 3
NCT02248883 Boehringer Ingelheim Healthy December 2005 Phase 1
NCT02246998 Gilead Sciences HIV-1 Infection December 2014 Phase 4
NCT00335686 Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA HIV Infections October 2003 Phase 4
NCT02346487 Drugs for Neglected Diseases|UNITAID|French Development Agency HIV September 2015 Phase 3
NCT00335192 Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA HIV January 2005 Phase 4
NCT00872417 Peking Union Medical College|Ministry of Science and Technology of the People´s Republic of China Acquired Immune Deficiency Syndrome|HIV Infections March 2009 Phase 4
NCT01705223 National Center for AIDS/STD Control and Prevention, China CDC AIDS August 2012 Phase 2
NCT00096746 Bristol-Myers Squibb HIV Infection November 2004
NCT00385957 Hospital Clinic of Barcelona HIV Infections Phase 4
NCT00039741 National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|PENTA Foundation HIV Infections August 2002 Phase 2|Phase 3
NCT01815736 Gilead Sciences HIV|HIV Infections March 27, 2013 Phase 3
NCT01641367 AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID) HIV-1 Infection October 2012 Phase 4
NCT02603107 Gilead Sciences HIV-1 Infection November 20, 2015 Phase 3
View MoreCollapse
References
Molecular Weight

720.94

Formula

C₃₇H₄₈N₆O₅S₂

CAS No.

155213-67-5

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO; H2O:< 0.1 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Purity: 99.55%

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ritonavir
Cat. No.:
HY-90001
Quantity: